Serina Therapeutics draws first $5M tranche from $20M note for SER-252 Parkinson's trial

Serina Therapeutics, Inc.

Received $5 million initial tranche under up to $20 million convertible note financing agreement.
Proceeds to fund registrational Phase 1b trial of SER-252 for advanced Parkinson's disease.
IND submitted to FDA and HREC approval received in Australia; global trial initiation in Q4 2025.
Phase 1b trial design: randomized, double-blind, placebo-controlled with SAD (n=40) and MAD (n=48) cohorts.
Subsequent tranches tied to development milestones including patient enrollment in the clinical trial.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.